ArticlePolymers2026
pH and Glucose Dual-Responsive Hybrid Polymeric Smart Insulin Carrier for Diabetes Treatment.
Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects.Journal of functional biomaterials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose-responsive smart insulin delivery systems that mimic the pancreatic insulin release system can improve the health and quality of life of patients with diabetes. In this study, a spherical drug delivery carrier encapsulating insulin was developed to achieve improved glucose accessibility and a rapid pH response using polyhedral oligomeric silsesquioxane (POSS) as a sterically stabilizing structure. Highly sensitive poly(acrylic acid) (PAA)-POSS-aminophenylboronic acid (APBA)@insulin (386 ± 69 nm), a spherical drug delivery carrier encapsulating insulin, was synthesized using POSS, a hydrophobic material, and PAA and APBA, which respond to pH and glucose, respectively. The drug carrier has dual reactivity with pH and glucose, and the synthesis of the carrier was confirmed through Fourier transform infrared (FT-IR) spectroscopy, which verified that the particles were stable at each pH through the zeta-potential data. In particular, PAA-POSS-APBA@insulin exhibited highly sensitive drug delivery characteristics, in which the backbone of PAA was expanded under acidic conditions (around pH 5.0) and insulin bound to the boronic acid inside could rapidly and selectively react with trace amounts of glucose. PAA-POSS-APBA@insulin nanoparticles exhibited no HeLa cell cytotoxicity up to a high concentration of 640 μg/mL, and the cell growth rate increased with the concentration, indicating biocompatibility. The average blood glucose level of diabetic mice treated with POSS-APBA@insulin (4.0 IU/kg) decreased for >6 h and remained stable. Thus, PAA-POSS-APBA@insulin can function as a stimulatory-responsive drug carrier targeting hyperglycemic environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.